We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Concerta Exclusivity May Hinge on Outcome of Actos Battle
Generic Concerta Exclusivity May Hinge on Outcome of Actos Battle
January 15, 2013
The FDA may be withholding a final 180-day exclusivity decision for Mallinckrodt’s Concerta generic until an appeals court resolves a legal battle over Actos generics that could dictate what types of regulatory filings lead to an exclusivity reward, a legal expert says.